规模最大的新冠病毒试验首先测试重新利用的药物。 - Suppr

Suppr

超能文献

Biggest COVID-19 trial tests repurposed drugs first.

出版信息

Nat Biotechnol. 2020 May;38(5):510. doi: 10.1038/s41587-020-0528-x.

DOI:10.1038/s41587-020-0528-x

PMID:32393915

Abstract

摘要

相似文献

Biggest COVID-19 trial tests repurposed drugs first.

Nat Biotechnol. 2020 May;38(5):510. doi: 10.1038/s41587-020-0528-x.

Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.

Am J Trop Med Hyg. 2020 Jun;102(6):1154-1155. doi: 10.4269/ajtmh.20-0262.

Some drugs for COVID-19.

Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50.

The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.

Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.01127-20.

Clinical Trials of Repurposed Antivirals for SARS-CoV-2.

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.

Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.

Trials. 2020 Jun 3;21(1):473. doi: 10.1186/s13063-020-04382-3.

Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.

BMJ Open. 2020 Sep 21;10(9):e041437. doi: 10.1136/bmjopen-2020-041437.

Race to find COVID-19 treatments accelerates.

Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.

Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.

Int J Antimicrob Agents. 2020 Oct;56(4):106143. doi: 10.1016/j.ijantimicag.2020.106143. Epub 2020 Aug 25.

Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.

Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.

引用本文的文献

Recent Advances of COVID-19 Modeling Based on Regenerative Medicine.

Front Cell Dev Biol. 2021 Oct 25;9:683619. doi: 10.3389/fcell.2021.683619. eCollection 2021.

Single paternal dexamethasone challenge programs offspring metabolism and reveals multiple candidates in RNA-mediated inheritance.

iScience. 2021 Jul 16;24(8):102870. doi: 10.1016/j.isci.2021.102870. eCollection 2021 Aug 20.

Therapeutic approaches against coronaviruses acute respiratory syndrome.

Pharmacol Res Perspect. 2021 Feb;9(1):e00691. doi: 10.1002/prp2.691.

Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.

Comput Struct Biotechnol J. 2021;19:1-15. doi: 10.1016/j.csbj.2020.11.056. Epub 2020 Dec 6.

CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target.

SLAS Discov. 2021 Mar;26(3):336-344. doi: 10.1177/2472555220973597. Epub 2020 Nov 18.

Repurposing existing drugs for COVID-19: an endocrinology perspective.

BMC Endocr Disord. 2020 Sep 29;20(1):149. doi: 10.1186/s12902-020-00626-0.

Severe Autoimmune Hemolytic Anemia in COVID-19 İnfection, Safely Treated with Steroids.

Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020053. doi: 10.4084/MJHID.2020.053. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验